A scoping review published in the World Journal of Pediatric Surgery highlights Europe’s inconsistent efforts to screen for biliary atresia (BA), a leading cause of pediatric liver transplants. Researchers from Geneva University Hospitals found that while some countries have adopted effective tools like stool color cards (SCC), most lack national programs, delaying critical diagnoses. The study calls for urgent, unified action to integrate cost-effective screening with emerging technologies like AI.
Biliary atresia, which requires surgical intervention within the first 60 days of life, often goes undetected due to fragmented screening practices. The review analyzed data from across Europe, revealing stark disparities: Switzerland, France, and Germany have national SCC programs, while others rely on localized pilots or lack initiatives entirely. SCCs, when paired with clear referral guidelines, significantly reduce diagnostic delays—yet physician hesitancy and logistical barriers persist.
The study also explored innovative solutions, such as Italy’s PopòApp and Germany’s AI-powered stool analysis, which could enhance accuracy and scalability. Serum bilirubin testing, though more expensive, offers broader liver disease detection and could complement SCC programs. However, progress is hindered by financial constraints and a lack of political will, as seen in the UK’s stalled bilirubin research.
“Europe has no shortage of expertise or technology—what’s missing is coordinated action,” said Professor Barbara E. Wildhaber, senior author of the study. “Simple tools like SCCs, combined with digital innovations and clinician engagement, could save countless infants—but we must act now.”
The research underscores the need for hybrid screening models tailored to regional healthcare systems, alongside education and advocacy. With BA-related infant mortality at stake, Europe must bridge the gap between evidence and implementation to ensure timely diagnoses and better outcomes for vulnerable newborns.
Add comment